Last updated: May 7, 2024
Sponsor: University of Giessen
Overall Status: Active - Recruiting
Phase
N/A
Condition
Covid-19
Treatment
pulmonary vascular dysfunction
pulmonary vascular function
Clinical Study ID
NCT05374577
KKS-300
Ages > 18 All Genders
Study Summary
Eligibility Criteria
Inclusion
Inclusion Criteria:
- Age ≥ 18 years, patients with a suspected diagnosis of post/long-COVID-19 syndrome whopresent to our pneumology or infectious disease outpatient clinic or correspondingward from the start of the study and whose SARS-CoV-2 infection was diagnosed at least 3 and not longer than 18 months prior to presentation
- Patients at least 3 and not longer than 18 months after a SARS-CoV-2 infection withoutpost/long-COVID-19 syndrome who present to our post-infection outpatient clinic forfollow-up
Exclusion
Exclusion Criteria:
- Patients who refuse to participate in the study
- Severe underlying chronic pulmonary, cardiac, or systemic disease (e.g., Chronicobstructive pulmonary disease (COPD), severe heart failure, neuromuscular disease)that was diagnosed prior to acute COVID-19 disease and whose progression appearslikely as the cause of dyspnea
- Other non pneumologic causes of dyspnea (e.g., hemoglobin < 100 g/L)
- Unstable or acute disease (e.g., acute infection, acute renal failure, acute coronarysyndrome)
- Inability to perform spiroergometry, including transient orthopedic problems,contraindications to central venous and arterial catheter placement (e.g., severebleeding tendency).
Study Design
Total Participants: 200
Treatment Group(s): 2
Primary Treatment: pulmonary vascular dysfunction
Phase:
Study Start date:
April 15, 2022
Estimated Completion Date:
June 30, 2025
Study Description
Connect with a study center
Natascha Sommer
Giessen,
GermanyActive - Recruiting
Not the study for you?
Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.